Talzenna prostate cancer competitor market share us iqvia fda?

Short answer:
- Talzenna (talazoparib) is not approved for prostate cancer in the US. Therefore, there is no FDA-approved market share for Talzenna in prostate cancer.

What this means for “competitor market share” in the US:
- The PARP inhibitors that do have approvals for metastatic castration-resistant prostate cancer (mCRPC) or related prostate cancer settings are olaparib (Lynparza), rucaparib (Rubraca), and niraparib (Zejula). Talazoparib does not appear in that indication today, so its share in the US PCa market is effectively zero.
- Among approved PARP inhibitors for PCa, olaparib generally holds the largest share, with rucaparib and niraparib having smaller shares depending on the specific patient population and gene alterations. Exact percentages vary by quarter and data source.

On IQVIA data and FDA status:
- IQVIA market-share figures are proprietary and updated quarterly. To give precise percentages, I’d need the specific quarter or report you want.
- If you’re looking for the latest numbers, I can help interpret IQVIA data you provide or point you to the latest FDA labeling and company filings for Talzenna’s approved indications.

Would you like me to pull the most recent IQVIA figures for PARP inhibitors in mCRPC (by quarter) and compare them, or would you prefer a summary of FDA labeling for Talzenna and its current approvals? If you have a date or quarter in mind, I can tailor the answer.